Citius Pharmaceuticals, Inc. CTXR 深 滬
等待開盤 09-20 09:30:00 美东时间
0.5481
+0.038
+7.47%
華盛通- 最 高0.5798
- 今 開0.54
- 成交量 187.44万股
- 最 低 0.52
- 昨 收 0.51
- 總市值 8714.79万
- 52周最高 1.07
- 市盈率 靜 --
- 換手率 1.18%
- 52周最低 0.48
- 委 比 -35.29%
- 總股本 1.59亿
- 歷史最高 5.49
- 量 比 3.19
- 振 幅 11.73%
- 歷史最低 0.34
- 每 手 1
- 風險率 0.11%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多快讯 | citius pharmaceuticals - 红地瑞同意部分延期，无需支付罚款，以期望Citius Oncology Inc的里程碑付款
Citius Pharmaceuticals - DR. Reddy's Agreed to Partial Deferral Without Penalty...
09-13 20:36
快讯 | Citius制药公司是Citius Oncology的义务担保人，在资产购买协议中
Citius Pharmaceuticals Inc - Co Is Guarantor of Obligations of Citius Oncology,...
09-13 20:36
Lymphir: A Promising Contender in the r/r CTCL Market with Strong Commercial Prospects
Analyst Michael Okunewitch of Maxim Group reiterated a Buy rating on Citius Pha...
08-13 19:28
Citius Pharma Q3 2024 GAAP EPS $(0.06) Misses $(0.05) Estimate
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.05) by 20 percent. This is unchanged from the same period last year.
08-13 05:41
快讯 | citius pharmaceuticals第三季度每股收益美元-0.06
Citius Pharmaceuticals Q3 Basic EPS USD -0.06
08-13 05:28
快讯 | Citius Pharmaceuticals, Inc. 报告2024财年第三季度财务业绩并提供业务更新
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Result...
08-13 05:28
快讯 | Citius Pharmaceuticals三季度净利润美元指数为负1060万。
Citius Pharmaceuticals Q3 Net Income USD -10.6 Million
08-13 05:28
快讯 | Citius Pharmaceuticals完成子公司与TenX Keane的合并，组建Citius Oncology, Inc。
Citius Pharmaceuticals Completes Merger of Subsidiary With TenX Keane to Form C...
08-13 04:23
Catalyst Watch: Eyes on Walmart earnings, the July CPI print, and 13F filings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Seeking Alpha's earnings calendar for a full list of companies due to report....
08-10 03:00
Citius wins FDA nod for Lymphir in cutaneous T-cell lymphoma
Citius Pharmaceuticals (NASDAQ:CTXR) became a commercial-stage biopharma on Thursday as the U.S. FDA approved its lead asset, Lymphir, as a late-line option for cutaneous T-cell lymphoma, a skin-relat...
08-09 01:15
